Biogen and AbbVie have announced the voluntary withdrawal of their multiple sclerosis drug Zinbryta from all markets worldwide following dangerous brain inflammation in seven patients in Europe.
The Opium Withdrawal Syndrome drugs in development market research report provides comprehensive information on the therapeutics under development for Opium Withdrawal Syndrome, complete with analysis ...
The withdrawal came amid increased scrutiny of the drug by the European Medicines Agency (EMA). The EMA in July began a review of voxelotor after data from a clinical trial showed that a higher ...
The move underscored the severity of the risks recently seen in studies of the drug, Oxbryta, in which researchers have reported a number of deaths among patients who were receiving it.